Don't Panic! Novartis Is Still Invested In CAR-T Despite 2Q Silence

Novartis AG's CAR-T cell therapy CTL019, set to be the first in this class to achieve a US FDA filing, might not be an immediate blockbuster owing to its tricky treatment logistics, small initial indication and a lack of physician and patient exposure, but it is still a game changer in immuno-oncology, says Dr. Oz Azam, Novartis's head of cell therapies.

RedBloodCellsOnWhite_1200x675

Novartis AG's cell therapy CTL019, a CAR-T (chimeric antigen receptor T-cells) product, caused a stir last month when the big pharma neglected to include the pipeline-leading therapy on a list of its upcoming potential blockbuster drugs during its second-quarter earnings presentation. But Dr. Oz Azam, global head of cell and gene therapies at Novartis, told Scrip this was not a big deal and indeed there were a number of explanations for the medicine's exclusion.

While Azam said he couldn’t comment directly on why Novartis's senior management team did not include CTL019 on a slide...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas